In late 2002, an epidemic of severe acute respiratory syndrome SARS spread throughout the Guangdong Province of China. By 2003, the respiratory system and gastrointestinal tract disease had affected more than 8,000 and killed more than 900 people in 25 countries before it was brought under control.

Today, biopharmaceutical companies are making advances for the prevention and treatment of diseases such as SARS through extensive research and development and DNA vaccines. Studies show that DNA vaccines have the potential to achieve desired response more quickly and cost effectively than conventional vaccines.

Vical Incorporated (Nasdaq: VICL) researches and develops biopharmaceutical products based on its patented DNA delivery technologies with potential applications to fight infections diseases or cancer.

The company today announced that the results from a phase I clinical trial of a DNA vaccine for SARS showed that the vaccine was well-tolerated and was successful in neutralizing antibody and T-cell immune

A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company focused on the development and commercialization of innovative medical treatments utilizing their proprietary polymer-based drug delivery systems.

The company’s proprietary Biochronomer™ technology, featuring bioerodible polymers intended to create controlled-release pharmaceuticals that improve treatments for diseases or health-threatening conditions, is their primary focus as they continue to advance the technology. The company’s lead product candidate is APF530, which is currently in a pivotal Phase III clinical trial for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting, or CINV.

The company has made significant investments in the development of their bioerodible drug delivery technologies, which have produced tangible results. Specifically, A.P. Pharma has developed a broad family of polymers consisting of unique attributes referred to as poly (ortho esters), under the trade name Biochronomer. This technology has been designed for use in drug delivery applications

Over the past nine years, the medical staff and computer experts at Performance Health Technologies, Inc. (PFMH) have collaborated on creating an advanced software and medical technology in order to create MotionTrack™, the company’s versatile proprietary technology platform. This innovative technology is the core of Performance Health’s device and computer software system that tracks and monitors motion and movement in real-time, ultimately providing instant visual feedback to the user and medical professionals.

From MotionTrack came Core:Tx®, a therapy tool that is continuing to gain interest from orthopedic surgeons and neurologists, occupational therapists and physical therapists, as well as speech pathologists. The Core:Tx® medical application is a motion-sensing system that allows users to gain visual feedback on their movements to enhance motor learning and manage muscular re-education. The technology was designed to leverage the unique features of Performance Health’s’ proprietary

Superlattice Power, Inc. (SLAT.OB), an emerging leader in lithium battery technology, has taken another step in developing a lithium ion battery capable of giving electric cars a range of at least 200 miles - a huge 50% increase over previous associated technologies.

One of the secrets of the company’s new lithium ion polymer battery is the unique material used in the cathode, the battery’s negative terminal. Superlattice has now begun in-house production of the material.

Many other materials have been tried, but have been problematic due to toxicity, high cost, and poor performance. The “Superlattice Structure” cathode materials, involving special transition metals, are non-toxic and significantly increase battery energy density, range, charge rate, and durability. Dr. Surajit Sengupta, director of Battery R&D for Superlattice, states: “Our objective is to create the next generation of Lithium Ion Polymer battery that is environmentally non-toxic, safe,

Superlattice Power Incorporated, a groundbreaking company in the field of lithium-powered batteries, is investigating plans to develop batteries for space flight applications. The experimental investigation into space flight applications involves a unique process for large scale production of two cathode materials for their ion-lithium batteries. The company has expanded both their production capabilities and their anode research capabilities in order to accommodate the necessary quantities.

The current cathode materials being used by Superlattice are very durable, and have a gravimetric capacity of 240 mAh/g, but in order for successful use in space flight applications, that will need to be increased to at least 280 mAh/g. Superlattice Power hopes to accomplish this through the use of their two new cathode materials, Li(LixNiyMnz)O2 and Li(LixNiaMnbCoc)O2, both of which are mainly composed of manganese. Their manganese structure makes them both environmentally friendly and

Axial Vector Engine Corporation is well known for their unique electric engine and internal combustion engine technologies. They have a reputation for their strength, durability and fuel efficiency, similarly the company’s Advisory Board has a well known reputation. The Advisory Board is comprised of distinguished senior executives who use their extensive experience and expertise in the industry to provide in-depth analysis regarding the strategic development of potential applications that utilize the company’s revolutionary new technologies.

The Chairman of the AVEC Advisory Board is Dr. Jack Walter, a long time engineer by trade with ties in the energy and manufacturing industries. Dr. Walter received his BS degree in Chemical Engineering, Summa Cum Laude, from the University of Florida, and his MS and PhD from the University of Pittsburgh. Having graduated with such an advanced education, he brings a wealth of knowledge

International Barrier Technology, Inc. (Barrier) develops, manufactures and markets proprietary fire retardant building materials designed to protect people and property from fire. Barrier owns the patent-protected Pyrotite Technology and has received “patent pending” status on the new $3.2 million manufacturing line process.

Its Pyrotite Technology, including building materials branded as Blazeguard®, uses a patented, non-toxic, non-combustible coating with an extraordinary capability: it releases water when exposed to the high temperatures of a fire. Pyrotite™ has potential applications in engineered wood products, paint, plastics, and expanded polystyrene. With over fifteen years of sales history and established brand identity, Barrier is leveraging its reputation and experience to pursue new applications, new regional US and international markets, and licensing opportunities.

The Blazeguard panels exceed “model” building code requirements in every targeted fire test and application, and are unique in combining properties that increase panel strength and minimize environmental and human impact.

Carbon Sciences is in the process of developing a futuristic technology that can turn potentially hazardous carbon dioxide (CO2) emissions into ecologically-friendly products. The CO2 is broken down and reconfigured into a chemical compound with a myriad of potential applications.

Today the company announced the grand opening of its new research and development center in Santa Barbara, California. The new facility is expected to bolster the development and commercialization of Carbon Sciences breakthrough technology. This puts the company in an excellent position, with the successful launch of this technology translating to Carbon Sciences’ break into a multi-billion dollar opportunity.

CEO Derek McLeish said, “We are very excited about securing and moving into our new and larger facility. This office and industrial space will be able to accommodate our aggressive growth plan over the next couple of years. With our core scientific and engineering team all under one roof, I believe